There are currently 2876 clinical trials in Houston, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including M D Anderson Cancer Center, University of Texas MD Anderson Cancer Center, Baylor College of Medicine and The University of Texas - MD Anderson Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies
NCT05136807
Recruiting
This study examines the quality of life in patients with monoclonal gammopathy of unknown significance and smoldering multiple myeloma. Collecting quality of life information from patients may help doctors learn more about the most common symptoms and concerns patients with monoclonal gammopathy of unknown significance and smoldering multiple myeloma may have.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Monoclonal Gammopathy of Undetermined Significance, Smoldering Plasma Cell Myeloma
Register for Updates
A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder
NCT05137262
Recruiting
This is a phase II randomized study of standard of care (SOC) neo-adjuvant cisplatin chemotherapy (NAC) versus NAC plus durvalumab in patients with either clinical or pathologic intra-pelvic node-positive urothelial carcinoma of the bladder. Patients with cTanyN1-3M0 via American Joint Committee on Cancer (AJCC) 8th edition staging30 will be considered tor enrollment in this trial. We plan to enroll 60 patients. Patients will be randomized 2:1 to the intervention arm with durvalumab plus NAC vs... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Urothelial Carcinoma, Bladder Cancer
Register for Updates
Molecular Epidemiology of Biliary Tree Cancers
NCT05179486
Recruiting
This study is to learn if certain risk factors (environmental, viral, behavioral, medical, and dietary), tumor markers, and genetic changes can predict the development and outcome of biliary tree cancers. Establishing biomarkers models from patients may help doctors to further understand how biliary tree cancer is affected by different treatments, and why some people's cancer responds differently than others.
Gender:
ALL
Ages:
All
Trial Updated:
05/13/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Cholangiocarcinoma, Malignant Digestive System Neoplasm
Register for Updates
Innovative Treatment of Chemotherapy-Induced Painful Peripheral Neuropathy in Adolescents and Young Adults With Cancer: A Two Arm Pilot Study
NCT05357469
Recruiting
To evaluate the efficacy and safety of Scrambler therapy (ST) for chemotherapy-induced painful peripheral neuropathy (CIPN), and the impact of ST on physical functioning and quality of life (QoL) in adolescents and young adults (AYA) cancer patients. In this proposed study, we will conduct a two-arm prospective, randomized wait-list controlled clinical trial to investigate the effectiveness of ST on pain and CIPN in AYAs with cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Peripheral Neuropathy
Register for Updates
Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients
NCT05529069
Recruiting
To learn if the combination of pirtobrutinib (also called LOXO-305) and venetoclax can help to control mantle cell lymphoma (MCL) that is relapsed (has come back) or refractory (has not responded to therapy).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Mantle Cell Lymphoma, Non Hodgkin Lymphoma, Hematologic Malignancy
Register for Updates
Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)
NCT05660083
Recruiting
This is a research study to test the safety and effectiveness of using the drug alpelisib together with chemotherapy (nab-paclitaxel) and a drug called L-NMMA in patients with HER2 negative metastatic or locally advanced metaplastic breast cancer, who have not responded to previous treatments. Participants in this study in addition to the standard care chemotherapy will also receive the drug alpelisib and L-NMMA. The therapies will be administered every 3 weeks (1 cycle) until disease progressi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2025
Locations: Houston Methodist Neal Cancer Center, Houston, Texas +1 locations
Conditions: HER2-negative Breast Cancer, Metastatic Breast Cancer, Metaplastic Breast Carcinoma, TNBC - Triple-Negative Breast Cancer
Register for Updates
IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)
NCT05742607
Recruiting
The study is intended to assess the safety and efficacy of neoadjuvant combination of IPH5201 and durvalumab in addition to standard chemotherapy and adjuvant combination of IPH5201 and durvalumab in untreated patients with resectable, early-stage (stage II to IIIA) non-small cell lung cancer (NSCLC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2025
Locations: Millennium Research & Clinical Development, Houston, Texas
Conditions: Non Small Cell Lung Cancer
Register for Updates
A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A
NCT05911763
Recruiting
This is a prospective, observational, multi-center longitudinal cohort study to describe the real-world effectiveness, safety and treatment usage of efanesoctocog alfa in patients with hemophilia A treated per standard of care in the US and Japan. Patients will be enrolled in the study after the introduction of efanesoctocog alfa in the hemophilia treatment landscape in each study country. Decision to initiate treatment with commercially available efanesoctocog alfa will be made by the treating... Read More
Gender:
ALL
Ages:
All
Trial Updated:
05/13/2025
Locations: Gulf States Hemophilia and Thrombophilia Center- Site Number : 8400029, Houston, Texas
Conditions: Hemophilia A
Register for Updates
PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma
NCT05922904
Recruiting
To learn about the effects of brentuximab vedotin and pembrolizumab in combination with doxorubicin and dacarbazine when given to patients who have Stage II cHL with bulky mediastinal disease or advanced cHL (Stage III or IV) and who have not received treatment for the disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Hodgkin Lymphoma
Register for Updates
A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activity of Venetoclax in Combination With Oral Decitabine/Cedazuridine (ASTX727) in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)
NCT06191978
Recruiting
To find a recommended dose of ASTX727 (cedazuridine/decitabine) in combination with venetoclax for pediatric patients with relapsed AML.
Gender:
ALL
Ages:
Between 2 years and 18 years
Trial Updated:
05/13/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Acute Myeloid Leukemia
Register for Updates
Enhancing Brain Connectivity in Schizophrenia Through Neuromodulation (Study 1)
NCT06345963
Recruiting
Patients with schizophrenia spectrum disorder (SSD) will be exposed to active repetitive transcranial magnetic stimulation (rTMS) from H coil for improving white matter integrity.
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
05/13/2025
Locations: The University of Texas Health Science Center, Houston, Houston, Texas
Conditions: Schizophrenia
Register for Updates
SMP-3124LP in Adults With Advanced Solid Tumors
NCT06526819
Recruiting
An Open-label, Phase I Dose Escalation and Phase 2 Dose Expansion Study to Assess Safety, Tolerability, Preliminary Antitumor Activity of SMP 3124LP in Adults with Advanced Solid Tumors
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Solid Tumor
Register for Updates